Sign up
Pharma Capital

SCYNEXIS reveals positive interim data from its Phase 3 FURI study

SCYNEXIS, Inc. (NASDAQ:SCYX) President & CEO Dr. Marco Taglietti sat down with Proactive Investors at the BIO CEO & Investor Conference in New York.

The biotechnology company's lead product candidate is ibrexafungerp (formerly known as SCY-078), an IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections

 

View full SCYX profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.